



RETEVMO
(selpercatinib)

Pre - PA Allowance

None

Prior-Approval Requirements

Diagnoses

Patient must have **ONE** of the following:

1. Locally advanced or metastatic non-small cell lung cancer (NSCLC)
 - a. 18 years of age or older
 - b. *RET* fusion-positive, as detected by an FDA-approved test
2. Advanced or metastatic medullary thyroid cancer (MTC)
 - a. 2 years of age or older
 - b. *RET*-positive mutation, as detected by an FDA-approved test
 - c. Patient requires systemic therapy
3. Advanced or metastatic thyroid cancer
 - a. 2 years of age or older
 - b. *RET* fusion-positive, as detected by an FDA-approved test
 - c. Patient requires systemic therapy
 - d. Radioactive iodine-refractory (if radioactive iodine is appropriate)
4. Locally advanced or metastatic solid tumors
 - a. 2 years of age or older
 - b. *RET* fusion-positive, as detected by an FDA-approved test
 - c. Disease has progressed on or following prior systemic treatment **OR** patient has no satisfactory alternative treatment options

AND ALL of the following:

1. Prescriber agrees to monitor AST, ALT, and blood pressure
2. Prescriber agrees to monitor for QT interval prolongation
3. Any pre-existing hypocalcemia, hypokalemia, or hypomagnesemia will be corrected prior to starting Retevmo therapy
4. Females of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Retevmo and for 1 week after the last dose
5. Males with female partners of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Retevmo and for 1 week after the last dose



**BlueCross
BlueShield**

Federal Employee Program.

**RETEVMO
(selpercatinib)**

Prior - Approval Limits

Quantity 320 mg per day

Duration 12 months

Prior – Approval *Renewal* Requirements

Diagnoses

Patient must have **ONE** of the following:

1. Locally advanced or metastatic non-small cell lung cancer (NSCLC)
 - a. 18 years of age or older
2. Advanced or metastatic medullary thyroid cancer (MTC)
 - a. 2 years of age or older
3. Advanced or metastatic thyroid cancer
 - a. 2 years of age or older
4. Locally advanced or metastatic solid tumors
 - a. 2 years of age or older

AND ALL of the following:

1. **NO** disease progression or unacceptable toxicity
2. Prescriber agrees to monitor AST, ALT, and blood pressure
3. Prescriber agrees to monitor for QT interval prolongation
4. Females of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Retevmo and for 1 week after the last dose
5. Males with female partners of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Retevmo and for 1 week after the last dose

Prior - Approval *Renewal* Limits

Same as above